Generic Daklinza (Daclatasvir )
Daklinza
Daklinza (daclatasvir) is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. Daklinza is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis.
Package
Price
Per Pills
Savings
60 mg x 28 pills
$540.99
$19.32
$0.00
Buy Now
Next orders 10% discount
+ Free standard airmail service
60 mg x 56 pills
$912.99
$16.30
$169.12
Buy Now
Next orders 10% discount
+ Free standard airmail service
Product Description

Daklinza - good, agree

Monitor warfarin, antidiabetics, CYP substrates with narrow therapeutic index; may need to adjust these. Figure 1. This medicine had Daklizna accelerated assessment. Daclatasvir, the active substance in Daklinza, blocks the action of a protein in the hepatitis C virus called NS5A which Daklinzq essential for the virus to multiply. You will need liver function tests during treatment and for several months after you stop using this medicine. See also: Daklinza side effects in more detail. Monthly newsletter. How it works Daclatasvir, the active substance in Daklinza, blocks the action of a protein in the hepatitis C virus called NS5A which is essential for the virus to multiply. Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin[16] as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir. Twitter Facebook Vimeo SoundCloud. Therapy Class NS5A replication complex inhibitor. For Phase III trials, ACPS provides customised services for central clinical trial coordination such as quality management; pharmacovigilance; investigator training and support, including set-up of trial-specific interactive webpages; and regulatory compliance, including trial master file TMF management. Authorisation details. Daaklinza SVR rates in genotype 3-infected patients with cirrhosis receiving daclatasvir with sofosbuvir for 12 weeks. For recommended treatment regimens and duration based on HCV genotype and patient population: see full labeling. Daklinza [1]. Daklinza daclatasvir Profile.

Common use
The active ingredient present in is daclatasvir – 60 mg.
Daklinza is a drug for the treatment of hepatitis C (HCV). Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA. Daklinza is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infections.
It is advised to avoid pregnancy during combination treatment with Daklinza and sofosbuvir with ribavirin for 6 months after completion of treatment.

Dosage and direction
The recommended dosage of Daklinza is 60 mg, taken orally, once daily, with or without food.
Recommended Treatment Regimen and Duration for Daklinza
Genotype 1:
Without cirrhosis - Daklinza + sofosbuvir for 12 weeks
Compensated (Child-Pugh A) cirrhosis - Daklinza + sofosbuvir for 12 weeks
Decompensated (Child-Pugh B or C) cirrhosis - Daklinza + sofosbuvir + ribavirin for 12 weeks
Post-transplant - Daklinza + sofosbuvir + ribavirin for 12 weeks
Genotype 3:
Without cirrhosis - Daklinza + sofosbuvir for 12 weeks
Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis - Daklinza + sofosbuvir + ribavirin for 12 weeks
Post-transplant - Daklinza + sofosbuvir + ribavirin for 12 weeks
For specific dosage recommendations for sofosbuvir, refer to the prescribing information.

Precautions
The concomitant use of Daklinza and other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeutic effect of Daklinza and possible development of resistance, dosage adjustments of concomitant medications or Daklinza, possible clinically significant adverse reactions from greater exposures of concomitant drugs or Daklinza.
Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with sofosbuvir in combination with another HCV direct-acting antiviral, including Daklinza. A fatal cardiac arrest was reported in a patient receiving a sofosbuvir-containing regimen (ledipasvir/sofosbuvir). Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for this bradycardia effect is unknown.
For patients taking amiodarone who have no alternative treatment options and who will be coadministered Daklinza and sofosbuvir need cardiac monitoring for the first 48 hours of coadministration, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.

Contraindications
Drugs that are Contraindicated with Daklinza:
Anticonvulsants - phenytoin, carbamazepine
Antimycobacterial agents - rifampin
Herbal products - St. John’s wort (Hypericum perforatum)

Possible side effect
Most common side effects occurred during the trials in combination with sofosbuvir (with or without ribavirin), with peginterferon alfa/ribavirin, with asunaprevir, or with asunaprevir/peginterferon alfa/ribavirin are such: fatigue, headache, pruritus, insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia, rash, asthenia, irritability, myalgia, anemia, pyrexia, cough, dyspnea, neutropenia, diarrhea, arthralgia, neutropenia, anemia, thrombocytopenia, and lymphopenia.
If you take Daklinza with sofosbuvir and you also take a heart rhythm medicine called amiodarone: This combination of medicines can cause dangerous side effects on your heart.

Drug interaction
Potential for Other Drugs to Affect Daklinza (clinically relevant increase in concentration):
HIV antiviral agents - Atazanavir with ritonavirb; Indinavir; Nelfinavir; Saquinavir
Other antiretrovirals - Cobicistat-containing antiretroviral regimens e.g. atazanavir/cobicistat,
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Anticoagulants - Dabigatran etexilate mesylate
Strong inhibitors of CYP3A (eg, clarithromycin, itraconazole, ketoconazole, ritonavir) may increase the plasma levels of daclatasvir.
Potential for Daklinza to Affect Other Drugs (clinically relevant decrease in concentration):
Non-nucleoside reverse transcriptase inhibitors (NNRTI) - Efavirenzb; Etravirine; Nevirapine
Moderate CYP3A inducers (see also HIV antiviral agents) - Examples: bosentan, dexamethasone, modafinil,
nafcillin, rifapentine.
Daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP). Administration of Daklinza may increase systemic exposure to medicinal products that are substrates of P-gp, OATP 1B1 or 1B3, or BCRP, which could increase or prolong their therapeutic effect or adverse reactions.

Missed dose
Take Daklinza every day at the regularly scheduled time with or without food. It is important not to miss or skip doses and to take Daklinza for the duration that is recommended by the physician. For instructions for missed doses of other agents in the regimen, refer to the respective prescribing information.

Overdose
There is no known antidote for overdose of Daklinza. Treatment of overdose with Daklinza should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. Because daclatasvir is highly protein bound (>99%), dialysis is unlikely to significantly reduce plasma concentrations of the drug.

Storage
Store Daklinza tablets at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Store away from moisture and heat. Keep all drugs out of the reach children and pets.

Disclaimer
We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Women's Health

Talking about women's health we usually mean a number of issues that are associated with women's physiology and anatomy. These issues usually includes gynecological diseases, pregnancy and breastfeeding, menopause, contraception and diseases that are peculiar only to women sex.

Gynecological diseases usually includes infectious diseases that are transmitted through the sexual intercourse. These may be viral, bacterial or fungal infection. The gynecological infections usually manifest in the form of inflammation, edema, redness, itching, discharges, pain in the pelvic area.

Menstruation, pregnancy and breastfeeding are related to the women's reproductive system. Menstruation is a physiological process manifested in rejection of the functional endomethrium layer and vaginal bleeding. Usually a women have a regular menstrual cycle. The disorders of the menstrual cycle can be caused by the hormonal changes, infectious diseases.

Pregnancy includes such issues as

  • Impregnation
  • Carrying of pregnancy and those changes that take place in the women's organism during the pregnancy
  • Act of delivery

If we talk about women's health in women over 45 years we usually talk about 2 conditions : menopause and osteoporosis. Menopause is a period in the women's health when her menstruation stops. In this period a women's organism begins to produce less sex hormones such as estrogens and progestogens. In this period many women complain on hot flashes, night sweats and others. In the period of menopause women usually relieve hormonal replacement therapy.

Another condition that is closely related to menopause is osteoporosis. Osteoporosis is a disease of the bones that becomes fragile and more susceptible to fractures. The treatment of osteoporosis includes life style changes, proper nutrition and certain medication such as Fosamax and Evista.